From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
Event | Galcanezumab 120 mg N = 129 n (%) | Galcanezumab 240 mg N = 141 n (%) |
---|---|---|
Patient with ≥1 TEAE | 106 (82.2) | 121 (85.8) |
Injection site pain | 22 (17.1) | 28 (19.9) |
Nasopharyngitis | 23 (17.8) | 18 (12.8) |
Upper respiratory tract infection | 9 (7.0) | 21 (14.9) |
Injection site reaction | 15 (11.6) | 13 (9.2) |
Back pain | 12 (9.3) | 15 (10.6) |
Sinusitis | 14 (10.9) | 13 (9.2) |
Nausea | 10 (7.8) | 9 (6.4) |
Injections site erythema | 9 (7.0) | 9 (6.4) |
Arthralgia | 8 (6.2) | 8 (5.7) |
Influenza | 8 (6.2) | 8 (5.7) |
Dizziness | 5 (3.9) | 9 (6.4) |
Injection site bruising | 5 (3.9) | 8 (5.7) |
Myalgia | 8 (6.2) | 3 (2.1) |
Weight increased | 7 (5.4) | 4 (2.8) |